Ceva (NASDAQ:CEVA) announced a landmark licensing agreement with a major U.S. software and AI platform company to support a custom AI silicon program aimed at next-generation intelligent computing devices.
Ionis Pharmaceuticals (NASDAQ:IONS) announced it completed patient enrollment in the pivotal pediatric cohort of its global Phase 3 REVEAL clinical study evaluating its investigational RNA-targeted medicine, obudanersen.
Pharvaris (NASDAQ:PHVS) announced the FDA accepted its regulatory application for its 20 mg hereditary angioedema on-demand treatment capsule.
Maximus (NYSE:MMS) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.33 per share to reward equity investors.
Lindsay (NYSE:LNN) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.38 per share.
AtaiBeckley (NASDAQ:ATAI) announced it completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating VLS-01 for treatment-resistant depression.
AEVEX (NYSE:AVEX) announced it secured a $17.5 million follow-on defense contract under its Global Solutions business segment to continue delivering critical intelligence services.
Natera (NASDAQ:NTRA) announced publication of new clinical data in JAMA Oncology evaluating its Signatera molecular residual disease (MRD) test in patients with resected colorectal liver metastases (CRLM).
High Tide (NASDAQ:HITI) said it has approved a Temporary Shareholder Rights Plan alongside an Amended and Restated Shareholder Rights Plan, both dated June 26, 2026.
Clarivate (NYSE:CLVT) said it has agreed to sell its Life Sciences & Healthcare (LS&H) segment to Altaris for a total consideration of $600 million.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
